The company said its revenues rose 9% in Q2 2024 and 7% year-to-date, citing growth from the Growth Portfolio and Eliquis, partially offset by Revlimid.

1. 01

   The company said its revenues rose 9% in Q2 2024 and 7% year-to-date, citing growth from the Growth Portfolio and Eliquis, partially offset by Revlimid.

2. 02

   The company said GAAP EPS for Q2 fell $0.16, while non-GAAP EPS rose $0.32. Year-to-date, GAAP EPS fell $7.11 and non-GAAP EPS fell $6.13. The company cited one-time Acquired IPRD charges from the Karuna asset acquisition and the SystImmune collaboration ($6.29) as a factor.

3. 03

   The company said operating cash flow for the year-to-date period rose $303 million compared with 2023, cash used in investing activities increased $20.4 billion, and cash provided by financing activities increased $15.8 billion. The company attributed the 2024 net borrowing of $13.2 billion mainly to funding for recent acquisitions.

4. 04

   The company said it completed the acquisitions of Karuna, RayzeBio and Mirati in 2024, and entered into a BL-B01D1 co-development and co-commercialization collaboration with SystImmune. It also said it entered into a worldwide capacity reservation and supply agreement with Cellares for the manufacture of CAR-T cell therapies.

Key figures

Quarter ended June 30, 2024

Revenue

$12.2B

Net income

$1.7B

EPS

$0.83

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.